Business Context and Reporting Period
This Form 8-K filing by Bone Biologics Corp (BBLG) is dated September 27, 2023. The report addresses a critical regulatory event concerning the company's listing status on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on compliance with listing standards rather than financial performance metrics.
Material Changes
- Delisting Notice: The company received a written notice from Nasdaq staff on September 27, 2023, stating it failed to comply with the $1.00 per share minimum bid price requirement (Listing Rule 5550(a)(2)).
- Compliance Status: Due to a previously imposed mandatory Panel Monitor (disclosed May 19, 2023), the company is ineligible for a standard compliance period to regain standing.
- Staff Determination: Nasdaq staff has determined to delist the company's securities (Common Stock and Warrants) from the Nasdaq Capital Market.
Outlook, Risks, and Management Commentary
- Appeal Process: Management plans to request a hearing before a Nasdaq Hearings Panel to appeal the delisting determination. This request will stay the delisting action pending the Panel's decision.
- Compliance Plan: The company intends to present a plan for regaining and sustaining compliance at the hearing.
- Contingency: If delisted, the company expects its securities to trade on the over-the-counter (OTC) Markets platform.
- Risks: There is no assurance that the Panel will grant an extension or that the company will ultimately regain compliance. The filing includes standard forward-looking statement disclaimers regarding these uncertainties.
Investor Verification Checklist
- Verify the current trading status of BBLG and BBLGW on Nasdaq versus OTC Markets.
- Monitor the filing of the formal appeal request to the Nasdaq Hearings Panel.
- Review the company's specific plan for regaining the $1.00 minimum bid price (e.g., reverse stock split).
- Check for subsequent 8-K filings regarding the outcome of the Nasdaq Hearings Panel.